PURPOSE: The impact of diabetes mellitus (DM) and metformin use on biochemical recurrence (BCR) in patients treated with radical prostatectomy (RP) remains controversial. METHODS: We retrospectively evaluated 6,863 patients who underwent RP for clinically localized PC between 2000 and 2011. Univariable and multivariable Cox regression models addressed the association of DM and metformin use with BCR. RESULTS: Overall, 664 patients had a diagnosis of DM from which 287 (43 %) were on metformin and 377 (57 %) were on anti-diabetics other than metformin. DM and metformin were not associated with any clinicopathologic features (p values >0.05). Within a median follow-up of 25 months (interquartile range 35 months), 774 (11.3 %) patients experienced BCR. Actuarial 5-year biochemical-free survival was 83 % for non-diabetic, 79 % for diabetic patients without metformin use, and 85 % for diabetic patients with metformin use (log rank p = 0.17). In uni- and multivariable Cox regression analyses with the non-diabetic group as referent, DM without metformin use (HR = 0.99; 95 % CI 0.75-1.30, p = 0.65) and DM with metformin use (HR = 0.84, 95 % CI 0.58-1.22, p = 0.36) were not associated with BCR after RP. A subgroup analysis stratified by nodal status, surgical margins, tumor stage, and Gleason sum did not reveal any significant association between DM, use of metformin and risk of BCR. CONCLUSIONS: We found no association between DM or metformin use and cancer-specific features or BCR in patients treated with RP. The effect of DM and metformin on complications, wound healing and overall survival needs to be assessed in similar cohorts.
PURPOSE: The impact of diabetes mellitus (DM) and metformin use on biochemical recurrence (BCR) in patients treated with radical prostatectomy (RP) remains controversial. METHODS: We retrospectively evaluated 6,863 patients who underwent RP for clinically localized PC between 2000 and 2011. Univariable and multivariable Cox regression models addressed the association of DM and metformin use with BCR. RESULTS: Overall, 664 patients had a diagnosis of DM from which 287 (43 %) were on metformin and 377 (57 %) were on anti-diabetics other than metformin. DM and metformin were not associated with any clinicopathologic features (p values >0.05). Within a median follow-up of 25 months (interquartile range 35 months), 774 (11.3 %) patients experienced BCR. Actuarial 5-year biochemical-free survival was 83 % for non-diabetic, 79 % for diabeticpatients without metformin use, and 85 % for diabeticpatients with metformin use (log rank p = 0.17). In uni- and multivariable Cox regression analyses with the non-diabetic group as referent, DM without metformin use (HR = 0.99; 95 % CI 0.75-1.30, p = 0.65) and DM with metformin use (HR = 0.84, 95 % CI 0.58-1.22, p = 0.36) were not associated with BCR after RP. A subgroup analysis stratified by nodal status, surgical margins, tumor stage, and Gleason sum did not reveal any significant association between DM, use of metformin and risk of BCR. CONCLUSIONS: We found no association between DM or metformin use and cancer-specific features or BCR in patients treated with RP. The effect of DM and metformin on complications, wound healing and overall survival needs to be assessed in similar cohorts.
Authors: Stephen A Boorjian; James A Eastham; Markus Graefen; Bertrand Guillonneau; R Jeffrey Karnes; Judd W Moul; Edward M Schaeffer; Christian Stief; Kevin C Zorn Journal: Eur Urol Date: 2011-12-07 Impact factor: 20.096
Authors: Axel Heidenreich; Joaquim Bellmunt; Michel Bolla; Steven Joniau; Malcolm Mason; Vsevolod Matveev; Nicolas Mottet; Hans-Peter Schmid; Theo van der Kwast; Thomas Wiegel; Filliberto Zattoni Journal: Eur Urol Date: 2010-10-28 Impact factor: 20.096
Authors: Navid Sadeghi; James L Abbruzzese; Sai-Ching J Yeung; Manal Hassan; Donghui Li Journal: Clin Cancer Res Date: 2012-03-31 Impact factor: 12.531
Authors: Sarah-Maria Fendt; Eric L Bell; Mark A Keibler; Shawn M Davidson; Gregory J Wirth; Brian Fiske; Jared R Mayers; Matthias Schwab; Gary Bellinger; Alfredo Csibi; Akash Patnaik; Marie Jose Blouin; Lewis C Cantley; Leonard Guarente; John Blenis; Michael N Pollak; Aria F Olumi; Matthew G Vander Heiden; Gregory Stephanopoulos Journal: Cancer Res Date: 2013-05-17 Impact factor: 12.701
Authors: Sao Jiralerspong; Shana L Palla; Sharon H Giordano; Funda Meric-Bernstam; Cornelia Liedtke; Chad M Barnett; Limin Hsu; Mien-Chie Hung; Gabriel N Hortobagyi; Ana M Gonzalez-Angulo Journal: J Clin Oncol Date: 2009-06-01 Impact factor: 44.544
Authors: Saira Khan; Jianwen Cai; Matthew E Nielsen; Melissa A Troester; James L Mohler; Elizabeth T H Fontham; Laura H Hendrix; Laura Farnan; Andrew F Olshan; Jeannette T Bensen Journal: Prostate Date: 2017-03-06 Impact factor: 4.104
Authors: A D Raval; D Thakker; A Vyas; M Salkini; S Madhavan; U Sambamoorthi Journal: Prostate Cancer Prostatic Dis Date: 2015-02-10 Impact factor: 5.554
Authors: Marco Randazzo; Josef Beatrice; Andreas Huber; Rainer Grobholz; Lukas Manka; Stephen F Wyler; Felix F Chun; Franz Recker; Maciej Kwiatkowski Journal: World J Urol Date: 2014-10-31 Impact factor: 4.226
Authors: Brian Winters; Stephen Plymate; Steven B Zeliadt; Sarah Holt; Xiaotun Zhang; Elaine Hu; Daniel W Lin; Colm Morrissey; Bryan Wooldridge; John L Gore; Michael P Porter; Jonathan L Wright Journal: Prostate Date: 2015-07-22 Impact factor: 4.104
Authors: Ilir Agalliu; Steve Williams; Brandon Adler; Lagu Androga; Michael Siev; Juan Lin; Xiaonan Xue; Gloria Huang; Howard D Strickler; Reza Ghavamian Journal: Cancer Causes Control Date: 2015-03-14 Impact factor: 2.506
Authors: R M Joentausta; P M Kujala; T Visakorpi; T L J Tammela; T J Murtola Journal: Prostate Cancer Prostatic Dis Date: 2016-08-09 Impact factor: 5.554